Keeping Hope Alive—Why the Schlueters Rally for Medical Research
Richard and Michelle Schlueter attended the Rally for Medical Research to advocate for NIH funding after budget cuts delayed his treatment.
Progress Against Cancer
Richard and Michelle Schlueter attended the Rally for Medical Research to advocate for NIH funding after budget cuts delayed his treatment.
The FDA approved pembrolizumab and berahyaluronidase alfa-pmph as an injectable therapy for multiple tumor types. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex) for subcutaneous (under the...
Researchers are helping advance ovarian cancer care with breakthroughs that are reshaping treatment and early detection approaches.
Cancer survivors profiled over the past 15 years in the AACR Cancer Progress Reports shared updates on their lives and the progress made against cancer.
Combination of targeted therapy and chemotherapy prolongs survival in lung cancer, and FDA approves a chemotherapy-releasing device to treat bladder cancer.
FDA expands selumetinib approval to include pediatric patients as young as 1 year with inoperable plexiform neurofibromas. The U.S. Food and Drug Administration (FDA) has approved selumetinib (Koselugo) granules and capsules for pediatric patients...
The FDA has approved a delivery system that, once inserted into the bladder, delivers a local dose of the drug gemcitabine. The U.S. Food and Drug Administration (FDA) has approved a gemcitabine intravesical system...
The second AACR Childhood Cancer Predisposition Workshop gathered experts from around the world to refine surveillance strategies, expanding recommendations to nearly 100 syndromes.
New research is redefining the role of surgery, revealing approaches to help cancer patients preserve their organs, function, and identity without compromising outcomes.
Rising prostate cancer rates reignite questions about screening guidelines, and a government report describing the health risks of alcohol may never be published.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More